Intravenous nanopeptide CAQK improves motor function and reduces astroglial activation after rat spinal cord injury
Background
Spinal cord injury (SCI) leads to severe motor, sensory, and autonomic dysfunctions, with neurological outcomes heavily influenced by secondary injury processes like inflammation and neuronal death. Current treatments often fall short in effectively mitigating this secondary damage and promoting functional recovery. CAQK is a unique homing peptide known to target central nervous system injury sites, previously showing benefits in traumatic brain injury. This study explores its potential to enhance motor recovery and provide neuroprotection specifically in SCI models, leveraging its targeted delivery mechanism.
Study Design
Twelve female Sprague-Dawley rats underwent C5 right-sided spinal cord hemicontusion to model SCI. Animals were randomized to receive either intravenous CAQK 2.5 mg/kg or saline daily for 7 days, starting 1 hour post-injury. Motor performance was longitudinally assessed using the Irvine, Beatties, and Bresnahan (IBB) Forelimb Recovery Scale (0-9 scale) at 1, 2, 5, and 8 weeks. Following behavioral assessments, histological analysis was performed to evaluate astroglial activation (via GFAP staining) and axonal preservation (via NFM staining). An in vitro neuroprotection assay also evaluated CAQK's effects on neuronal network complexity.
Results
All animals initially exhibited motor deficits post-injury. CAQK-treated rats demonstrated significantly improved motor recovery compared to saline controls across multiple time points. By week 8, the IBB score for CAQK-treated rats was 7 compared to 3 for controls (p = 0.01). Histological examination revealed significantly reduced astroglial activation in the CAQK group, with GFAP levels at 0.1±0.01 versus 0.7±0.2 in untreated controls (p = 0.002). Furthermore, axonal preservation was increased in the CAQK group, indicated by NFM levels of 0.3±0.06 compared to 0.1±0.06 in controls (p = 0.03).
Key Findings
- CAQK-treated rats showed significantly improved motor recovery by week 8 (IBB score 7 vs. 3 for controls; p = 0.01).
- Astroglial activation was significantly reduced in the CAQK group (GFAP: 0.1±0.01 vs. 0.7±0.2 for controls; p = 0.002).
- Axonal preservation was significantly increased in CAQK-treated rats (NFM: 0.3±0.06 vs. 0.1±0.06 for controls; p = 0.03).
- In vitro, CAQK significantly enhanced neuronal network complexity (p < 0.05).
Why It Matters
This study highlights CAQK as a promising therapeutic candidate for spinal cord injury, offering a targeted approach to neuroprotection and functional recovery. The demonstration of improved motor outcomes and reduced astroglial activation suggests that CAQK could mitigate secondary injury processes, which are critical determinants of long-term disability. The intravenous administration route and specific dosing protocol (2.5 mg/kg daily for 7 days) provide a clear starting point for future translational research, potentially leading to more effective clinical strategies for SCI patients. Its ability to home to injury sites could minimize off-target effects, making it an attractive option for a condition where systemic treatments often face challenges.
caqk
spinal-cord-injury
neuroprotection
motor-recovery
preclinical-animal
nanopeptide